Clonal evolution of chemotherapy-resistant urothelial carcinoma

Nature Genetics

Volumn 48, Issue 12, 2016, Pages 1490-1499

  Faltas, Bishoy M ^a,b   Prandi, Davide ^c   Tagawa, Scott T ^a,b   Molina, Ana M ^a,b   Nanus, David M ^a,b   Sternberg, Cora ^d   Rosenberg, Jonathan ^e   Mosquera, Juan Miguel ^a,b   Robinson, Brian ^a,b   Elemento, Olivier ^a,b   Sboner, Andrea ^a,b   Beltran, Himisha ^a,b   Demichelis, Francesca ^a,b,c   Rubin, Mark A ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TRENTO   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; INTEGRIN; NERVE CELL ADHESION MOLECULE L1; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLONAL EVOLUTION; CLONAL VARIATION; CONTROLLED STUDY; CYSTECTOMY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; PHYLOGENY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; WHOLE EXOME SEQUENCING; CARCINOMA, TRANSITIONAL CELL; CELL CLONE; DRUG RESISTANCE; EXOME; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MUTAGENESIS; MUTATION; PATHOLOGY; SECONDARY; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOBEC-1 DEAMINASE; CARCINOMA, TRANSITIONAL CELL; CLONAL EVOLUTION; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; EXOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTAGENESIS; MUTATION; NEURAL CELL ADHESION MOLECULE L1; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84991628400     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3692     Document Type: Article

References (74)

1. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2010 (National Cancer Institute, Bethesda, Maryland, USA, 2013
2. von der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005
3. Clark, P.E. et al. Bladder cancer. J. Natl. Compr. Canc. Netw. 11, 446-475 (2013
4. Sternberg, C.N. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19, 2638-2646 (2001
5. Sternberg, C.N. et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50-54 (2006
6. Bellmunt, J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27, 4454-4461 (2009
7. Bellmunt, J. & Petrylak, D.P. New therapeutic challenges in advanced bladder cancer. Semin. Oncol. 39, 598-607 (2012
8. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014
9. Prandi, D. et al. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 15, 439 (2014
10. Nixon, K.C. The parsimony ratchet, a new method for rapid parsimony analysis. Cladistics 15, 407-414 (1999
11. Zheng, Y. et al. Identification of Pold2 as a novel interaction partner of protein inhibitor of activated STAT2. Int. J. Mol. Med. 30, 884-888 (2012
12. Lee, Y.S., Gregory, M.T. & Yang, W. Human Pol ? purified with accessory subunits is active in translesion DNA synthesis and complements Pol ? in cisplatin bypass. Proc. Natl. Acad. Sci. USA 111, 2954-2959 (2014
13. van Boxtel, R. et al. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ. 20, 1219-1229 (2013
14. Choi, E.J. et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget 7, 3506-3519 (2016
15. Greco, C. et al. E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma. Cancer Res. 70, 7674-7683 (2010
16. Wei, L., Li, Y. & Suo, Z. TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway. Int. J. Clin. Exp. Med. 8, 8599-8607 (2015
17. Zöller, M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer 9, 40-55 (2009
18. Kinsella, R.J. et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford) 2011, bar030 (2011
19. Plimack, E.R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959-967 (2015
20. Eke, I. & Cordes, N. Focal adhesion signaling and therapy resistance in cancer. Semin. Cancer Biol. 31, 65-75 (2015
21. Maiuthed, A. & Chanvorachote, P. Cisplatin at sub-toxic levels mediates integrin switch in lung cancer cells. Anticancer Res. 34, 7111-7117 (2014
22. Seguin, L., Desgrosellier, J.S., Weis, S.M. & Cheresh, D.A. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 25, 234-240 (2015
23. Tsutsumi, S. et al. L1 cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. J. Surg. Oncol. 103, 669-673 (2011
24. Weidle, U.H., Eggle, D. & Klostermann, S. L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res. 29, 4919-4931 (2009
25. Meier, B. et al. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res. 24, 1624-1636 (2014
26. Szikriszt, B. et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol. 17, 99 (2016
27. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
28. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012
29. Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600-606 (2016
30. Roberts, S.A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976 (2013
31. Liu, D. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094-1096 (2016
32. Van Allen, E.M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140-1153 (2014
33. Hoopes, J.I. et al. APOBEC3A and APOBEC3B preferentially deaminate the lagging strand template during DNA replication. Cell Rep. 14, 1273-1282 (2016
34. Lackey, L. et al. APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419, 301-314 (2012
35. Chelico, L., Pham, P. & Goodman, M.F. Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G. Phil. Trans. R. Soc. Lond. B 364, 583-593 (2009
36. Harris, R.S. & Liddament, M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4, 868-877 (2004
37. Faltas, B.M., Karir, B.S., Tagawa, S.T. & Rosenberg, J.E. Novel molecular targets for urothelial carcinoma. Expert Opin. Ther. Targets 19, 515-525 (2015
38. Knowles, M.A. & Hurst, C.D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25-41 (2015
39. Yoon, H. et al. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett. 316, 70-76 (2012
40. Stoeck, A. et al. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol. 104, 461-469 (2007
41. Sebens Müerköster, S. et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-Apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26, 2759-2768 (2007
42. Sebens Müerköster, S. et al. alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int. J. Oncol. 34, 243-253 (2009
43. Kiefel, H. et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh. Migr. 6, 374-384 (2012
44. Gast, D. et al. The RGD integrin binding site in human L1-CAM is important for nuclear signaling. Exp. Cell Res. 314, 2411-2418 (2008
45. Voura, E.B., Ramjeesingh, R.A., Montgomery, A.M. & Siu, C.H. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol. Biol. Cell 12, 2699-2710 (2001
46. Burgett, M.E. et al. Direct contact with perivascular tumor cells enhances integrin avβ3 signaling and migration of endothelial cells. Oncotarget http://dx.doi.org/ 10.18632/oncotarget.9700 (2016
47. Hodkinson, P.S. et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13, 1776-1788 (2006
48. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662-668 (1999
49. Zhang, H. et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-Activated protein kinase dependent pathway. Cancer 95, 896-906 (2002
50. Argyris, E.G. et al. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology 367, 440-451 (2007
51. Shain, K.H. & Dalton, W.S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 1, 69-78 (2001
52. Damiano, J.S. Integrins as novel drug targets for overcoming innate drug resistance. Curr. Cancer Drug Targets 2, 37-43 (2002
53. Hazlehurst, L.A. & Dalton, W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 20, 43-50 (2001
54. Hehlgans, S., Haase, M. & Cordes, N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 1775, 163-180 (2007
55. Cho, S. et al. Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM. MAbs 8, 414-425 (2016
56. Min, J.K. et al. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin. Cancer Res. 16, 3571-3580 (2010
57. Schäfer, H. et al. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett. 319, 66-82 (2012
58. Golubovskaya, V.M. Targeting FAK in human cancer: from finding to first clinical trials. Front. Biosci. (Landmark Ed.) 19, 687-706 (2014
59. Schultze, A. & Fiedler, W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs 19, 777-788 (2010
60. Rezaee, M., Sanche, L. & Hunting, D.J. Cisplatin enhances the formation of DNA single-And double-strand breaks by hydrated electrons and hydroxyl radicals. Radiat. Res. 179, 323-331 (2013
61. Zellweger, R. et al. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. J. Cell Biol. 208, 563-579 (2015
62. Roberts, S.A. & Gordenin, D.A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786-800 (2014
63. Chan, K. et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067-1072 (2015
64. Lipinski, K.A. et al. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer 2, 49-63 (2016
65. Beltran, H. et al. Whole-exome sequencing of metastatic cancer and iomarkers of treatment response. JAMA Oncol. 1, 466-474 (2015
66. Demichelis, F. et al. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res. 36, 2446-2456 (2008
67. Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298-305 (2016
68. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004
69. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015
70. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013
71. Jiang, Y., Soong, T.D., Wang, L., Melnick, A.M. & Elemento, O. Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. PLoS One 7, e40332 (2012
72. Romanel, A., Lago, S., Prandi, D., Sboner, A. & Demichelis, F. ASEQ: fast allele-specific studies from next-generation sequencing data. BMC Med. Genomics 8, 9 (2015
73. Ramos, A.H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423-E2429 (2015
74. Eilbeck, K. et al. The sequence ontology: a tool for the unification of genome annotations. Genome Biol. 6, R44 (2005).